Severe lactic acidosis in association with CD5⁺ large B-cell lymphoma

Abstract

Lactic acidosis is classified into type A and type B. In cases of type B lactic acidosis, it is important to consider underlying lymphomas, mostly B-cell types, such as intravascular large B-cell lymphoma (IVLBCL) or diffuse large B-cell lymphoma. Cluster of differentiation (CD) 5⁺ large B-cell lymphoma (LBCL) is well-known for its aggressive nature. We report here two cases of CD5⁺ LBCL that showed severe lactic acidosis (11.2 mmol/L and 15.9 mmol/L, respectively; reference range: 0.6-1.7) with hypoglycemia. Case 1 was a 79-year-old female who presented with multiple organ failure. CD5⁺ IVLBCL was diagnosed through a random skin biopsy in this patient. Case 2 was a 78-year-old female with bone marrow involvement by CD5⁺ LBCL cells and liver failure. The patient was also diagnosed pathologically as IVLBCL by liver biopsy. Both patients were under ventilator management and high-flow continuous hemodialysis and filtration. Plasma exchange was also employed. An anti-lymphoma regimen (a 50% dose-reduced etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) was introduced on day 11 and day 2 of hospitalization for cases 1 and 2, respectively. In Case 1, lactic acidosis was normalized within day 17, and the patient survived longer than 8 weeks, while in Case 2, lactic levels did not improve until her death on day 16 of hospitalization. In conclusion, prompt recognition of type B lactic acidosis and early diagnostic biopsy are essential for improving outcomes in aggressive CD5⁺ IVLBCL, highlighting the need for novel therapeutic strategies.

Keywords

CD5+ large B-cell lymphoma / Lactic acidosis / Intravascular large B-cell lymphoma / Random skin biopsy / Liver biopsy / Chemotherapy / Ventilator management / Continuous hemodialysis and filtration

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, editors., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008. p. 233-237.

[2] Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood. 2002; 99:815-821. doi: 10.1182/blood.v99.3.815

[3] Miyazaki K. [ CD5-positive DLBCL: Molecular basis and treatment strategies]. Rinsho Ketsueki. 2015; 56:1038-1044. doi: 10.11406/rinketsu.56.1038

[4] Duan X, Lapus A, Brown RE, Chen L. Intravascular large B-cell lymphoma presenting as cholecystitis and pancytopenia: Case report with literature review. Ann Clin Lab Sci. 2011; 41:262-266.

[5] Ronny FMH, Black MA, Arbini AA. Intravascular large B-cell lymphoma with multi-organ failure presenting as a pancreatic mass: A case with atypical presentation and definite diagnosis postmortem. Autops Case Rep. 2017; 7:30-36. doi: 10.4322/acr.2017.034

[6] Sato M, Kuroda H, Yoshida M, et al. [Successful treatment with combination of plasma exchange and chemotherapy for CD5-positive primary hepatosplenic diffuse large B-cell lymphoma complicated with acute liver injury]. Rinsho Ketsueki. 2014; 55:958-964.

[7] Zhang X, Sun M, Zhang L, Shao H. Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma:A case report with literature review. Int J Clin Exp Pathol. 2013; 6(5):985-989.

[8] Yu D, Tang X, Xue H, Ao Y, Xie Y, Li X. Paraneoplastic syndrome in malignant lymphoma: A case report. Heliyon. 2023;9:e18968. doi: 10.1016/j.heliyon.2023.e18968

[9] Müller J, Radej J, Horak J, et al. Lactate: The fallacy of oversimplification. Biomedicines. 2023; 11:3192. doi: 10.3390/biomedicines11123192

[10] Deenadayalan V, Ganesan V, Shah M, Fidai S, Birch N. Lactic acidosis: A novel presentation of intravascular lymphoma. Cureus. 2023; 15(5):e39201. doi: 10.7759/cureus.39201

[11] Englert P, Levy S, Vekemans M, De Wilde V. Intravascular lymphoma presenting with hypoxaemia, platypnoea and lactic acidosis. BMJ Case Rep. 2021; 14:e241067. doi: 10.1136/bcr-2020-241067

[12] Khanal P, Pokharel A, Bastola S. Severe lactic acidosis and hypoglycemia associated with burkitt lymphoma and the Warburg effect. Cureus. 2024; 16:e60985. doi: 10.7759/cureus.60985

[13] Looyens C, Giraud R, Silva IN, Bendjelid K. Burkitt lymphoma and lactic acidosis: A case report and review of the literature. Physiol Rep. 2021; 9:e14737. doi: 10.14814/phy2.14737

[14] Wang C, Lv Z, Zhang Y. Type B lactic acidosis associated with diffuse large B-cell lymphoma and the Warburg effect. J Int Med Res. 2022; 50:1-6. doi: 10.1177/03000605211067749

[15] Duriseti P, Vanegas YM, Jaber BL, Balakrishnan VS, Madias NE. Malignancy-induced lactic acidosis in adult lymphoma. Clin Nephrol. 2021; 95:1-21. doi: 10.5414/CN110116

[16] Ferreruela M, Raurich JM, Ayestarán I, Llompart-Pou JA. Hyperlactatemia in ICU patients: Incidence, causes and associated mortality. J Crit Care. 2017; 42:200-205. doi: 10.1016/j.jcrc.2017.07.039

[17] Wang Y, Huang Y, Yang J, Zhou FQ, Zhao L, Zhou H. Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis. Mil Med Res. 2018; 5:13. doi: 10.1186/s40779-018-0160-y

[18] Spiegelberg J, Lederer AK, Claus S, et al. Severe hyperlactatemia in unselected surgical patients: Retrospective analysis of prognostic outcome factors. BMC Surg. 2022; 22:312. doi: 10.1186/s12893-022-01729-2

[19] Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: A chameleon with multiple faces and many masks. Blood. 2018; 132:1561-1567. doi: 10.1182/blood-2017-04-737445

[20] Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): A clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007; 109:478-485. doi: 10.1182/blood-2006-01-021253

[21] Di Fonzo H, Contardo D, Carrozza D, et al. Intravascular large B cell lymphoma presenting as fever of unknown origin and diagnosed by random skin biopsies: A case report and literature review. Am J Case Rep. 2017; 18:482-486. doi: 10.12659/ajcr.903816

[22] MacGillivary ML, Purdy KS. Recommendations for an approach to random skin biopsy in the diagnosis of intravascular B-cell lymphoma. J Cutan Med Surg. 2023; 27(1):44-50. doi: 10.1177/12034754221130257

[23] Zamò A, Johnston P, Attygalle AD, Laurent C, Arber DA, Fend F. Aggressive B-cell lymphomas with a primary bone marrow presentation. Histopathology. 2020; 77(3):369-379. doi: 10.1111/his.14124

[24] Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018; 5:e609-e617. doi: 10.1016/S2352-3026(18)30177-7

[25] Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018; 36(5):733-739. doi: 10.1002/hon.2525

[26] Yang CF, Yu YT, Wang SH, et al. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: Implications for aggressiveness and immunotherapy. Pathology. 2024; 56(3):367-373. doi: 10.1016/j.pathol.2023.10.019

[27] Khan MS, McCubbin M, Nand S. Intravascular large B-cell lymphoma: A difficult diagnostic challenge. J Investig Med High Impact Case Rep. 2014;2:AQ5 2324709614526702. doi: 10.1177/2324709614526702

[28] Takeshige T, Harada N, Sekimoto Y, et al. Pulmonary intravascular large B-cell lymphoma (IVLBCL) disguised as an asthma exacerbation in a patient with asthma. Intern Med. 2017; 56:1885-1891. doi: 10.2169/internalmedicine.56.7613

[29] Sawa N, Ubara Y, Katori H, et al. Renal intravascular large B-cell lymphoma localized only within peritubular capillaries. Report of a case. Intern Med. 2007; 46:657-662. doi: 10.2169/internalmedicine.46.6333

[30] Kim MJ, Park HS, Yhim HY. Intravascular large B-cell lymphoma diagnosed via transjugular liver biopsy in a patient with liver dysfunction and thrombocytopenia: A case report. Medicine (Baltimore). 2017; 96:e6925. doi: 10.1097/MD.0000000000006925

[31] Enzan N, Kitadate A, Kono M. Optimizing random skin biopsies: A review of techniques and indications for intravascular large B-cell lymphoma. Int J Hematol. 2024; 119:619-625. doi: 10.1007/s12185-024-03757-5

[32] Nair R, Shah U. Lactic acidosis: A rare oncological emergency in solid tumors at presentation. Am J Med Sci. 2017; 353:402-406. doi: 10.1016/j.amjms.2016.05.001

[33] He YF, Wei W, Sun ZM, et al. Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma. Adv Ther. 2007; 24:505-509. doi: 10.1007/BF02848772

[34] Miyazaki K, Asano N, Yamada T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: A single-arm, open-label, phase II study. Haematologica. 2020; 105:2308-2315. doi: 10.3324/haematol.2019.231076

[35] Gupta GK, Jaffe ES, Pittaluga S. A study of PD-L1 expression in intravascular large B cell lymphoma: Correlation with clinical and pathological features. Histopathology. 2019; 75(2):282-286. doi: 10.1111/his.13870